Relative efficacy and safety of low molecular weight heparin preparations for non-hospital prophylaxis and treatment of venous thrombo-embolic disease British Columbia Office of Health Technology Assessment
Pharmacare currently faces the difficult task of coordinating its non-hospital low molecular weight heparin (LMWH) reimbursement policy with the diverse reimbursement policies found among hospitals in the British Columbia. As part of this coordination effort, Pharmacare asked the Therapeutics Initiative (TI) for an evidence-based opinion on the relative efficacy and safety of LMWH preparations.
Item Citations and Data
Attribution-NonCommercial-NoDerivs 2.5 Canada